GF Fund Management CO. LTD. Purchases Shares of 17,611 IDEXX Laboratories, Inc. (NASDAQ:IDXX)

GF Fund Management CO. LTD. purchased a new stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) during the fourth quarter, according to its most recent filing with the SEC. The firm purchased 17,611 shares of the company's stock, valued at approximately $7,281,000.

Other hedge funds have also modified their holdings of the company. Hurley Capital LLC acquired a new stake in shares of IDEXX Laboratories in the 4th quarter valued at approximately $29,000. Rialto Wealth Management LLC bought a new stake in IDEXX Laboratories during the 4th quarter worth approximately $30,000. Colonial Trust Co SC increased its stake in IDEXX Laboratories by 84.8% during the 4th quarter. Colonial Trust Co SC now owns 85 shares of the company's stock worth $35,000 after purchasing an additional 39 shares in the last quarter. Kestra Investment Management LLC bought a new stake in IDEXX Laboratories during the 4th quarter worth approximately $38,000. Finally, Itau Unibanco Holding S.A. increased its stake in IDEXX Laboratories by 540.0% during the 4th quarter. Itau Unibanco Holding S.A. now owns 96 shares of the company's stock worth $40,000 after purchasing an additional 81 shares in the last quarter. 87.84% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at IDEXX Laboratories

In other IDEXX Laboratories news, Director M Anne Szostak sold 1,260 shares of the firm's stock in a transaction on Wednesday, May 21st. The stock was sold at an average price of $512.34, for a total transaction of $645,548.40. Following the completion of the sale, the director now owns 1,801 shares of the company's stock, valued at $922,724.34. This trade represents a 41.16% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 0.98% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on IDXX shares. Bank of America increased their target price on IDEXX Laboratories from $475.00 to $535.00 and gave the stock a "neutral" rating in a research note on Tuesday, February 4th. Stifel Nicolaus increased their target price on IDEXX Laboratories from $460.00 to $510.00 and gave the stock a "hold" rating in a research note on Monday, May 19th. Barclays increased their target price on IDEXX Laboratories from $481.00 to $520.00 and gave the stock an "overweight" rating in a research note on Tuesday, February 4th. Wall Street Zen raised IDEXX Laboratories from a "hold" rating to a "buy" rating in a research note on Thursday, May 22nd. Finally, Morgan Stanley raised their price target on shares of IDEXX Laboratories from $548.00 to $558.00 and gave the stock an "overweight" rating in a research note on Monday, May 5th. Three analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $536.00.

IDEXX Laboratories Stock Up 0.2%

Shares of NASDAQ IDXX traded up $1.22 during trading hours on Thursday, hitting $515.55. The company had a trading volume of 362,408 shares, compared to its average volume of 650,163. The stock has a market capitalization of $41.46 billion, a P/E ratio of 48.32, a price-to-earnings-growth ratio of 3.41 and a beta of 1.52. The company has a quick ratio of 0.95, a current ratio of 1.31 and a debt-to-equity ratio of 0.28. IDEXX Laboratories, Inc. has a 1-year low of $356.14 and a 1-year high of $530.60. The firm's 50 day moving average is $446.06 and its 200-day moving average is $436.13.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The company reported $2.96 EPS for the quarter, beating the consensus estimate of $2.93 by $0.03. The company had revenue of $998.43 million during the quarter, compared to the consensus estimate of $998.25 million. IDEXX Laboratories had a return on equity of 55.82% and a net margin of 22.78%. The firm's revenue for the quarter was up 3.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.71 EPS. On average, analysts expect that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.